Hubbry Logo
SedationSedationMain
Open search
Sedation
Community hub
Sedation
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Sedation
Sedation
Sedation
View on Wikipedia
from Wikipedia
Anesthetist

Sedation is the reduction of irritability or agitation by administration of sedative drugs, generally to facilitate a medical procedure or diagnostic procedure. Examples of drugs which can be used for sedation include isoflurane, diethyl ether, propofol, etomidate, ketamine, pentobarbital, lorazepam and midazolam.[1]

Medical uses

[edit]

Sedation is typically used in minor surgical procedures such as endoscopy, vasectomy, or dentistry and for reconstructive surgery, some cosmetic surgeries, removal of wisdom teeth, or for high-anxiety patients.[2] Sedation methods in dentistry include inhalation sedation (using nitrous oxide), oral sedation, and intravenous (IV) sedation. Inhalation sedation is also sometimes referred to as "relative analgesia".[citation needed]

Sedation is also used extensively in the intensive care unit so that patients who are being ventilated tolerate having an endotracheal tube in their trachea. It can also be used during a long term brain EEG to help patient relax.[citation needed]

Risks

[edit]

There are studies claiming that sedation accounts for 40 percent to 50 percent procedure-related complications.[3] Airway obstruction, apnea, and hypotension are not uncommon during sedation and require the presence of health professionals who are suitably trained to detect and manage these problems. Aside from the respiratory depression, risks also include unintended levels of sedation, postoperative somnolence, aspiration,[4] and adverse reactions to sedation medications.[5] Complications could also include perforation, bleeding, and the stimulation of vasovagal reflexes.[6] To avoid sedation risks, care providers conduct a thorough pre-sedation evaluation and this process includes pre-sedation history and physicals with emphasis on the determining characteristics that indicate potential risks to the patient and potential difficult airway management.[7] This process can also reveal if the sedation period needs to be prolonged or additional therapeutic procedures are required.[8]

Levels of sedation

[edit]

Sedation scales are used in medical situations in conjunction with a medical history in assessing the applicable degree of sedation in patients in order to avoid under-sedation (the patient risks experiencing pain or distress) and over-sedation (the patient risks side effects such as suppression of breathing, which might lead to death).[citation needed]

Examples of sedation scales include MSAT (Minnesota Sedation Assessment Tool), UMSS (University of Michigan Sedation Scale), the Ramsay Scale (Ramsay, et al. 1974) and the RASS (Richmond Agitation-Sedation Scale).[citation needed]

The American Society of Anesthesiologists defines the continuum of sedation as follows:[9]

  • Minimal sedation – normal response to verbal stimuli.
  • Moderate sedation – purposeful response to verbal/tactile stimulation. (This is usually referred to as "conscious sedation")
  • Deep sedation – purposeful response to repeated or painful stimulation.
  • General anesthesia – unarousable even with painful stimulus.

In the United Kingdom, deep sedation is considered to be a part of the spectrum of general anesthesia, as opposed to conscious sedation.

In addition to the aforementioned precautions, patients should be interviewed to determine if they have any other condition that may lead to complications while undergoing treatment. Any head, neck, or spinal cord injuries should be noted as well as any diagnosis of osteoporosis.[citation needed]

Intravenous sedation

[edit]

The most common standard conscious sedation technique for adults is intravenous sedation using Midazolam.

Indications:[citation needed]

  • Reduced dental anxiety and phobia
  • Traumatic or prolonged dental procedures
  • Patients with gag reflex
  • Medical conditions potentially aggravated by the stress of dental treatment
  • Special care (mild intellectual or physical disability)
  • Some disorders involving its spasticity due to its muscle relaxant properties

Contraindications:[citation needed]

  • Uncooperative patient
  • Psychologically immature individuals
  • Patients unable to provide a suitable escort
  • Difficult oral surgery or prolonged surgical procedure
  • Muscle diseases or diseases which cause muscle wastage
  • ASA III or above
  • Allergy or hypersensitivity to benzodiazepines
  • Pregnancy and breast feeding
  • History of psychiatric disorders
  • Kidney or liver dysfunction
  • Acute pulmonary insufficiency
  • Preexisting respiratory conditions as patients are susceptible to respiratory depression
  • Alcohol or drug addiction
  • Lack of visible superficial veins

Sedation for pediatric patients

[edit]

Present drugs commonly used to sedate children: Methohexital; Thiopental; Benzodiazepines; Diazepam; Midazolam; Ketamine; Opioids; Morphine; Meperidine; Fentanyl.

Whenever it is necessary to sedate a child, one must consider the type of procedure planned (painful or nonpainful), the duration of the procedure (important in choosing the appropriate sedative), the underlying medical condition of the patient (proper fasting, contracted blood volume, interaction with other medications, and intact mechanisms of drug elimination), the need for anxiolysis or narcosis, and experience with alternative techniques or routes of administration.

A child undergoing a procedure that is nonpainful (e.g., CT scan or small laceration infiltrated with local anesthetic) does not require a narcotic. Conversely, a child undergoing a painful procedure may require an opioid.[10]

See also

[edit]

References

[edit]
[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Sedation

View on Grokipedia
from Grokipedia
Sedation is the medically induced reduction of , agitation, or through the administration of drugs, resulting in a state of calmness, relaxation, or drowsiness that facilitates patient comfort during diagnostic, therapeutic, or surgical procedures. It encompasses a continuum of depth, from minimal anxiolysis to deep sedation bordering on general , where patients exhibit varying degrees of responsiveness to stimuli while maintaining spontaneous ventilation in lighter levels. Primarily employed in procedural settings such as emergency departments, endoscopy suites, and dental offices, sedation aims to minimize patient anxiety, pain, and movement to enable safe and effective completion of interventions like biopsies, colonoscopies, or minor surgeries. It is distinct from general anesthesia by preserving the patient's ability to maintain airway patency and respond in moderate levels, though transitions between depths can occur unpredictably, necessitating vigilant oversight. Common indications include alleviating discomfort in uncooperative patients, such as children or those with severe anxiety, while avoiding the full risks associated with deeper unconsciousness. The levels of sedation are classified by the (ASA) as follows: minimal sedation (anxiolysis), where patients respond normally to verbal commands with unaffected respiratory and cardiovascular functions; moderate sedation (also known as conscious sedation), characterized by purposeful responses to verbal or tactile stimulation without need for airway intervention; and deep sedation, where arousal requires repeated or painful stimuli and may involve partial airway support. Beyond deep sedation lies general , marked by unarousability and mandatory , though procedural sedation typically targets moderate to deep levels for balance between efficacy and safety. These distinctions guide clinical practice, with patient selection based on age, comorbidities, and procedure complexity to mitigate risks like oversedation. Medications for sedation commonly include benzodiazepines such as for anxiolysis and amnesia, often combined with opioids like for analgesia in procedural contexts. Other agents encompass for rapid-onset deep sedation, for dissociative effects preserving airway reflexes, and barbiturates like for pediatric use, selected based on desired depth, duration, and reversal potential. Administration routes vary—intravenous for precise , oral or intranasal for milder cases—and reversal agents like for benzodiazepines or for opioids are available to counteract effects if needed. Safety during sedation demands continuous monitoring of oxygenation via , ventilation through , circulation with and assessments, and clinical for responsiveness and airway patency. Potential complications include respiratory depression, , and aspiration, which are minimized by pre-procedure evaluation, fasting guidelines, and provider training in . Post-sedation recovery involves until baseline alertness returns, with discharge criteria ensuring safe ambulation and .

Overview and Fundamentals

Definition and Purpose

Sedation refers to a medically induced state of calm, relaxation, or partial suppression of consciousness, achieved through the administration of sedative medications to alleviate anxiety, discomfort, or during diagnostic or therapeutic procedures, while generally preserving the patient's to verbal commands or tactile stimulation. This state, often termed conscious or procedural sedation, allows patients to tolerate interventions that might otherwise be distressing, without progressing to full . The primary purposes of sedation in clinical practice include facilitating the performance of minor surgical, diagnostic, or therapeutic procedures, such as endoscopies or wound repairs, by minimizing patient movement and distress; serving as an adjunct to analgesia for control during these interventions; and aiding behavioral management in uncooperative or agitated patients, including children or those with cognitive impairments. These objectives enhance procedural efficiency and patient comfort, contributing to safer and more effective medical care. , procedural sedation is utilized in over 20 million invasive procedures annually, underscoring its widespread application across healthcare settings. Sedation is distinct from natural sleep, a physiological restorative process driven by endogenous mechanisms rather than external drugs; from hypnosis, which induces relaxation through psychological suggestion without pharmacological alteration of consciousness; and from general anesthesia, a deeper intervention that eliminates protective airway reflexes and requires due to complete unresponsiveness. The concept of sedation has evolved from its origins in early 20th-century , where barbiturates were first employed as sedative-hypnotics for calming effects, to the contemporary understanding of sedation as a dynamic continuum ranging from minimal anxiolysis to deeper states approaching anesthesia. This modern framework, formalized by the in the mid-1990s, emphasizes individualized dosing to navigate the spectrum safely.

Historical Context

The use of natural sedatives dates back to ancient civilizations, where from the plant was employed for its calming and pain-relieving effects. from around 3400 BCE document the cultivation of opium poppies for medicinal purposes, including sedation. In , the , dating to approximately 1550 BCE, describes opium mixtures used to sedate children and alleviate distress. Alcohol, derived from fermented beverages, was also widely utilized across Mesopotamian, Egyptian, and Greek societies for inducing relaxation and managing anxiety, often in ritual or therapeutic contexts. The marked significant advancements with the introduction of synthetic sedatives, expanding beyond natural substances. emerged in the as one of the first chemical sedatives, initially used for epilepsy but adopted for its calming properties in psychiatric care. , synthesized in 1832 and introduced clinically in 1869 by Mathias Liebreich, became the first widely used hypnotic agent for inducing sleep without the risks associated with opium. Barbiturates followed in 1903 with the synthesis of barbital by and Joseph von Mering, representing the initial class of synthetic sedatives that offered more predictable dosing but carried risks of overdose and dependence. In the mid-20th century, the development of in the 1950s revolutionized sedation by providing safer alternatives to barbiturates. Chlordiazepoxide, the first , was synthesized in 1955 and approved in 1960, offering effects with lower toxicity and reduced respiratory depression. This shift was accelerated by the tragedy of the early 1960s, where the sedative's link to severe birth defects prompted global regulatory reforms, emphasizing rigorous safety testing and favoring agents like benzodiazepines over riskier options. The late 20th and early 21st centuries saw further refinements in sedation practices, including the adoption of the continuum of depth of sedation model by the in 1999, which standardized levels from minimal to deep sedation for safer procedural use. , introduced in in 1986 and approved in the US in 1989, gained prominence for its rapid onset and short duration, transforming ambulatory . , an alpha-2 agonist approved by the FDA in 1999, emerged as a selective sedative sparing respiratory function, particularly in intensive care. Key milestones included the 1985 publication of the Mallampati classification, which improved airway risk assessment during sedation. In the , FDA warnings in highlighted neurodevelopmental risks of prolonged sedation in young children, influencing pediatric protocols. Amid the opioid crisis, the 2020s emphasized non-opioid alternatives to mitigate risks. Post-2000 developments featured target-controlled infusion systems, with second-generation pumps approved in 2003 for precise drug delivery based on pharmacokinetic models. By 2022–2025, AI-assisted dosing systems began integrating real-time patient data for automated adjustments, enhancing safety in closed-loop .

Pharmacological and Physiological Basis

Sedative Agents and Classes

Sedative agents are categorized into several major classes based on their , primary mechanisms, and clinical applications, with selection guided by factors such as procedure duration, patient age, and comorbidities. Benzodiazepines represent one of the most commonly used classes for sedation, providing anxiolysis, , and sedation through enhancement of GABA activity. Midazolam, a prototypical short-acting , exhibits an onset of action within 1 to 5 minutes when administered intravenously and has an elimination half-life of approximately 1 to 4 hours, making it suitable for brief procedures. Barbiturates, such as , were historically employed for sedation but are now rarely used due to their narrow , risk of respiratory depression, and potential for dependence. Non-benzodiazepine hypnotics, exemplified by , offer sedation with a more selective affinity for GABA-A receptors, though they are primarily indicated for sleep induction and used adjunctively in procedural settings. Opioids like serve as adjuncts to enhance analgesia during sedation, often combined with other agents to mitigate pain without primary sedative effects. Novel agents such as , an alpha-2 , provide sedation with minimal respiratory depression and are favored in intensive care for their properties. Other important categories include intravenous s, agents, and inhaled sedatives. , a widely used intravenous anesthetic, induces sedation with a rapid onset of less than 1 minute and recovery within 5 to 15 minutes, attributed to its lipid emulsion formulation allowing quick redistribution. , a agent, uniquely preserves airway reflexes and respiratory drive while providing analgesia and sedation, making it valuable for patients at risk of aspiration. Inhaled agents like , typically administered at 50% concentration in oxygen, produce mild sedation with rapid onset and offset, suitable for minor procedures due to its minimal cardiovascular impact. Recent developments include ultra-short-acting agents like remimazolam, an esterase-metabolized benzodiazepine approved by the FDA in 2020 for procedural sedation in adults, offering predictable recovery without accumulation in prolonged use. Ciprofol, a GABA-A agonist structurally related to propofol, has emerged as an alternative since its approval by the NMPA in China on December 15, 2020, for sedation during gastrointestinal endoscopy (with expanded indications including induction and maintenance of general anesthesia and sedation during intensive care by 2023), demonstrating higher potency and fewer adverse effects such as injection pain. Selection of sedative agents depends on procedure duration, with short-acting options like preferred for brief interventions and longer-acting ones avoided to minimize recovery time; patient age influences dosing, as elderly individuals require reduced amounts due to slower clearance; comorbidities, such as , contraindicate barbiturates owing to impaired metabolism. Typical dosing for in procedural sedation is 0.02 to 0.1 mg/kg intravenously, titrated to effect while monitoring for oversedation. Pharmacokinetics of key classes, particularly benzodiazepines, involve rapid absorption from the or intravenous administration, wide distribution due to high lipid solubility, hepatic metabolism primarily via 3A4 () enzymes leading to active or inactive metabolites, and renal elimination of conjugates. This profile allows for predictable but necessitates caution in patients with inhibitors, which can prolong effects.
ClassExampleOnset (IV)Half-LifeKey Considerations
Benzodiazepines1-5 min1-4 hoursAnxiolysis, amnesia; metabolism
Barbiturates5-10 min53-118 hoursRarely used; high risk in liver impairment
Non-benzodiazepine Hypnotics15-30 min (oral)2-3 hoursSelective GABA-A; adjunctive use
Alpha-2 Agonists5-10 min2 hoursMinimal respiratory depression
Intravenous Anesthetics<1 min2-24 hours (context-sensitive)Rapid recovery; hypotension risk
Dissociative AgentsKetamine1-2 min2-3 hoursPreserves reflexes; emergence reactions
Inhaled AgentsNitrous OxideImmediateMinutes (washout)Mild effects; 50% concentration typical
Novel BenzodiazepinesRemimazolam1-2 min<10 min (metabolites inactive)Ultra-short; FDA 2020 approval
GABA-A AgonistsCiprofol<1 min~2 hoursPropofol alternative; less injection pain

Mechanisms of Action

Sedatives primarily exert their effects through modulation of key neurotransmitters in the central nervous system (CNS), leading to inhibition of neuronal activity and reduced arousal. Benzodiazepines, a major class of sedatives, enhance the inhibitory actions of gamma-aminobutyric acid (GABA), the primary inhibitory neurotransmitter, by binding to the benzodiazepine site on GABA_A receptors. This allosteric modulation increases the frequency of chloride channel opening in response to GABA, resulting in greater chloride influx into neurons, membrane hyperpolarization, and decreased excitability. Sedating effects are predominantly mediated by GABA_A receptors containing the α1 subunit, which are enriched in brain regions involved in arousal and sleep regulation. Another prominent mechanism involves antagonism of excitatory neurotransmission. Ketamine, a dissociative sedative, acts primarily as a non-competitive antagonist at N-methyl-D-aspartate (NMDA) receptors, which are glutamate-gated ion channels critical for synaptic plasticity and arousal. By blocking NMDA receptor activation, ketamine disrupts excitatory signaling in thalamocortical pathways, producing dissociative states characterized by analgesia, amnesia, and sedation without significant respiratory depression at subanesthetic doses. Additional pathways contribute to sedative effects through diverse receptor interactions. Dexmedetomidine, a selective α2-adrenergic agonist, inhibits noradrenergic neurons in the locus coeruleus, a brainstem nucleus that serves as the primary source of norepinephrine in the brain, thereby reducing norepinephrine release and suppressing arousal signals to the cortex and thalamus. This leads to a cooperative sedation with preserved respiratory drive and analgesia. Opioids, such as morphine, bind to mu-opioid receptors in the CNS, including brainstem and cortical areas, to induce sedation via inhibition of ascending arousal pathways; this mechanism synergizes with their primary analgesic effects at the same receptors, enhancing overall therapeutic utility in pain-sedation contexts. Physiologically, sedatives depress the reticular activating system (RAS) in the brainstem, a network that maintains wakefulness by projecting excitatory signals to the cortex, resulting in generalized CNS suppression and reduced consciousness. These agents also produce dose-dependent impacts on vital functions: respiration is depressed through mu-opioid receptor-mediated inhibition in the pre-Bötzinger complex and GABAergic effects on respiratory centers, often leading to 20-50% reductions in minute ventilation during moderate sedation. Cardiovascular stability is generally preserved with agents like dexmedetomidine due to sympatholytic actions that minimize tachycardia, though others like opioids may cause mild bradycardia via vagal enhancement. The pharmacodynamics of sedative effects can be modeled using the Hill equation to describe receptor occupancy and resultant drug effect, particularly for GABA agonists like benzodiazepines: Effect=Emax⁡⋅[Drug]nEC50n+[Drug]n\text{Effect} = E_{\max} \cdot \frac{[\text{Drug}]^n}{\text{EC}_{50}^n + [\text{Drug}]^n} Here, Emax⁡E_{\max} is the maximum effect, [Drug][\text{Drug}] is the drug concentration, EC50\text{EC}_{50} is the concentration producing half-maximal effect, and nn is the Hill coefficient reflecting cooperativity (often >1 for GABA_A potentiators due to allosteric enhancement). This sigmoid relationship illustrates how low doses yield minimal hyperpolarization, while higher doses approach full receptor saturation and profound sedation. Recent studies using (fMRI) have revealed that sedation involves deactivation of the , a key region for executive function and consciousness, with reduced blood oxygen level-dependent (BOLD) signals correlating to diminished activity and impaired awareness.

Classification and Administration

Levels of Sedation

Sedation exists on a continuum of depth, ranging from minimal sedation (anxiolysis) to general , as defined by the (ASA). This model, originally approved in 1999 and amended in 2014, was last amended on October 23, 2024. It emphasizes the fluid nature of sedation states where patients can unintentionally progress to deeper levels. The ASA classification provides standardized criteria to guide , ensuring appropriate monitoring and intervention based on the patient's responsiveness, ventilatory function, and cardiovascular stability. The levels are differentiated by the degree of consciousness depression and physiological impacts:
  • Minimal Sedation (Anxiolysis): Patients respond normally to verbal commands, though cognitive function and coordination may be mildly impaired; ventilatory and cardiovascular functions remain unaffected, with no need for airway support.
  • Moderate Sedation/Analgesia (Conscious Sedation): Patients exhibit purposeful responses to verbal commands or light tactile stimulation; the airway is maintained independently, spontaneous ventilation is adequate, and cardiovascular function is typically stable without interventions.
  • Deep Sedation/Analgesia: Patients are not easily aroused but respond purposefully to repeated or painful stimuli; ventilatory function may be impaired, requiring potential airway assistance, while cardiovascular function is usually maintained.
  • General Anesthesia: Patients are unarousable even with painful stimulation; airway, ventilation, and often cardiovascular support are required due to frequent impairment of these functions.
These distinctions inform clinical decision-making, such as the need for rescue capabilities—providers administering moderate sedation must be prepared to manage deep sedation, while those handling deep sedation must address general risks. Assessment of sedation levels relies on validated tools to ensure precision and titrate agents accordingly. The , developed in 1974, categorizes sedation from 1 to 6 based on responsiveness: level 1 indicates an anxious and agitated patient; level 2 a cooperative and tranquil state; level 3 response only to commands; levels 4-5 asleep with brisk to sluggish responses to stimuli; and level 6 no response, akin to deep . A target of level 3 is often aimed for in moderate sedation to balance comfort and arousability. The , introduced in 2002, extends from +4 (combative) to -5 (unarousable), with 0 denoting alert and calm; it provides finer granularity for agitation and sedation in intensive care, where scores of -1 to -3 correspond to moderate sedation. The , an EEG-derived measure, quantifies cortical activity on a 0-100 scale; for moderate sedation, targets typically range from 70-85 to indicate purposeful responsiveness without excessive depth, though values below 60 signal deeper states requiring heightened monitoring. Transitions between levels occur dynamically due to pharmacodynamic variability, with risks of unintentional progression—particularly from moderate to deep sedation—in procedural settings like . For example, one study using meperidine and found deep sedation in 68% of patients. This deepening can compromise ventilation, necessitating prompt recognition to avoid or airway obstruction. Clinical implications include tailored monitoring; for instance, the ASA Standards for Basic Anesthetic Monitoring recommend capnography integration for real-time ventilation assessment during moderate to deep sedation, enhancing detection of . In pediatric contexts, adaptations emphasize higher vigilance for rapid deepening, as children under 6 years or with developmental delays frequently require deeper sedation for cooperation, prompting ASA-aligned guidelines to incorporate age-specific and ECG monitoring to mitigate risks.

Methods of Delivery

Sedation can be administered through various routes, each suited to specific clinical needs based on onset time, duration, and patient factors. The oral route involves swallowing medications like midazolam syrup, commonly used for premedication, with an onset of 30 to 60 minutes allowing for anxiolysis before procedures. Intranasal delivery, such as fentanyl spray, provides rapid onset within 5 to 10 minutes and is particularly effective for pediatric patients requiring quick analgesia and mild sedation without vascular access. Intravenous administration offers precise control, exemplified by propofol given as an initial bolus of 1 to 2 mg/kg followed by infusion, enabling rapid induction and titration for procedural sedation. Inhaled sedation, typically nitrous oxide delivered via a nasal mask, is highly titratable with concentrations adjusted from 20% to 70% to achieve desired anxiolysis while maintaining patient cooperation. Techniques for delivery emphasize and through incremental dosing. Conscious sedation protocols involve titrated administration of agents to reach a targeted level of relaxation, with sufficient intervals between doses to assess effects and avoid oversedation, as recommended by professional guidelines. Advanced methods include target-controlled (TCI) systems, which use pharmacokinetic models like the model for to predict and maintain plasma concentrations; this model employs a three-compartment approach where the central compartment concentration CpC_p is approximated as Cp=doseVdC_p = \frac{\text{dose}}{V_d}, adjusted for distribution volumes and elimination rates across compartments. Essential equipment supports accurate delivery and monitoring. Infusion pumps deliver precise intravenous rates for agents like , while vaporizers control inhaled gas mixtures such as . In certain cases, such as pediatric procedures or with agents like , atropine (0.02 to 0.04 mg/kg) may be used as to prevent . Recent advancements as of 2025 enhance non-invasive options. Oral dissolvable films incorporating have been for rapid transmucosal absorption in outpatient management of agitation, with minimal sedation effects. Subcutaneous routes, using continuous infusions via portable pumps, have gained traction in for sustained sedation with opioids or benzodiazepines, minimizing discomfort in end-of-life management. As of 2025, updates to TCI models, such as extended pharmacokinetic models for in diverse populations, improve precision in sedation delivery. Intravenous delivery excels in precision and rapid recovery, typically 15 to 30 minutes, ideal for procedures needing quick reversal, though it requires vascular access and monitoring. In contrast, oral methods offer simplicity and non-invasiveness for but involve slower onset and longer recovery of 1 to 2 hours, suitable for less urgent scenarios.

Clinical Applications

Procedural and Diagnostic Uses

Sedation plays a crucial role in facilitating comfort and during various non-surgical procedures and diagnostic interventions, allowing for safer and more efficient completion without the need for general . By achieving targeted levels such as minimal or moderate sedation, it minimizes discomfort, anxiety, and involuntary movements that could compromise procedural outcomes. In gastrointestinal , moderate sedation using combinations like and is standard practice to reduce anxiety, , and discomfort, enabling higher procedure completion rates and polyp detection. This approach has been shown to alleviate discomfort in the majority of cases, with studies indicating effective symptom relief during upper and lower . For instance, low-dose combined with narcotics and achieves moderate sedation levels that enhance procedural tolerance. For radiological diagnostics such as computed tomography (CT) and , minimal sedation is often employed to address , which affects 1% to 15% of patients and can otherwise prevent scan completion. Sedation in this context improves patient cooperation and reduces motion artifacts, particularly in pediatric cases where non-sedation success rates for MRI can reach 86% with supportive techniques, but pharmacological aid ensures reliable imaging quality when needed. In minor surgical procedures like incision and drainage, procedural sedation supplements local anesthetics such as lidocaine to manage and anxiety, especially in pediatric settings where it facilitates successful drainage without deeper . This is particularly useful for superficial , allowing quick intervention while maintaining patient stability. Diagnostic applications extend to , where moderate sedation permits verbal responsiveness while minimizing gag reflex and discomfort, and to , where deep sedation helps preserve hemodynamic stability during invasive assessments. In , this level of sedation supports routine flexible procedures, while for cardiac interventions, it balances analgesia with cardiovascular monitoring to avoid sympathetic tone reduction. The benefits of sedation in these contexts include enhanced patient cooperation, which reduces motion artifacts and improves diagnostic accuracy—for example, achieving up to 90% success in pediatric imaging scans—and shorter procedure times with certain sedation protocols. Overall, sedation success rates for elective procedures exceed 95%, with moderate sedation typically allowing recovery within 1 hour post-procedure. Recent advancements include telemedicine-guided sedation for remote diagnostics, enabling real-time anesthesiologist oversight during procedures since 2023, which expands access in underserved areas. Additionally, virtual reality (VR)-assisted anxiolysis serves as an adjunct to reduce sedation requirements in adults undergoing interventions such as endoscopy or minor diagnostics, promoting lower pharmacological doses through immersive distraction.

Therapeutic Uses in Critical Care

In intensive care units (ICUs), sedation is primarily employed to facilitate by ensuring patient comfort, reducing anxiety, and minimizing physiological stress responses such as or that could complicate respiratory support. infusions, titrated to achieve a (RASS) score of -2 to 0 for light sedation, are commonly used in mechanically ventilated adults to maintain hemodynamic stability and allow for periodic assessments of neurological status. Compared to benzodiazepines, has been associated with shorter durations of and reduced ICU length of stay in critically ill patients, with meta-analyses indicating improvements in ventilator-free days by up to 1-2 days on average. Delirium prevention represents a key therapeutic goal of sedation strategies in the ICU, where light sedation protocols help mitigate the risk of cognitive dysfunction that affects up to 80% of ventilated patients. The 2018 Pain, Agitation/Sedation, , Immobility, and Sleep Disruption (PADIS) guidelines from the Society of Critical Care Medicine (SCCM) recommend targeting light sedation (RASS 0 to -2) over deep sedation to decrease incidence while preserving during . A 2025 focused update to these guidelines further suggests over for achieving light sedation in ventilated adults, emphasizing its role in reducing without excessive respiratory depression. Protocols for sedation management in the ICU incorporate daily interruption trials to optimize outcomes, such as shortening duration and facilitating earlier from . A landmark published in the New England Journal of Medicine demonstrated that daily interruption of sedative infusions in mechanically ventilated patients reduced the duration of by 2.4 days and ICU length of stay by 3.5 days compared to continuous sedation. Multimodal approaches combining with , such as , are increasingly adopted to provide balanced analgesia and sedation, minimizing requirements and associated side effects like respiratory depression. Sedation adequacy, assessed via tools like the RASS, achieves optimal levels (within target range) in approximately 60-70% of ventilated patients under protocolized care, highlighting the need for frequent monitoring to adjust infusions. Beyond mechanical ventilation, sedation serves therapeutic roles in managing specific ICU conditions, including palliative care for terminal agitation and alcohol withdrawal syndrome. In palliative settings within the ICU, low-dose midazolam is administered subcutaneously or intravenously to alleviate refractory terminal restlessness, providing rapid symptom relief without hastening death when used proportionally to distress. For alcohol withdrawal, benzodiazepines like lorazepam or diazepam are titrated based on the Clinical Institute Withdrawal Assessment for Alcohol, Revised (CIWA-Ar) scale to prevent severe complications such as seizures or delirium tremens in at-risk patients. Recent advancements in SCCM guidelines, updated through 2025, incorporate (EEG) monitoring for in refractory agitation or cases, allowing precise titration of sedatives like to achieve therapeutic while avoiding oversedation.

Special Populations and Considerations

Pediatric Sedation

Pediatric sedation requires careful consideration of developmental , as children exhibit distinct pharmacokinetic and pharmacodynamic profiles compared to adults. For instance, children aged 2 to 11 years demonstrate increased hepatic clearance of sedative agents like , often approximately twice that of adults due to higher metabolic rates and greater liver blood flow per body weight. Additionally, anatomical differences in the pediatric airway, such as a relatively larger , narrower , and more compliant structures, elevate the risk of obstruction during sedation, with complications like occurring more frequently than in adults. These factors necessitate age-adjusted dosing and vigilant monitoring to prevent respiratory , particularly in infants and toddlers where airway patency is more precarious. Common sedative agents in pediatrics are selected for their safety profiles and routes of administration suited to non-invasive procedures. For diagnostic imaging in infants and young children, preferred oral or intranasal options include (0.2-0.5 mg/kg intranasal) or (2-3 mcg/kg intranasal), which provide reliable anxiolysis with minimal respiratory depression; chloral hydrate is infrequently used or avoided due to safety concerns, limited to low doses (10-25 mg/kg) in specific dental contexts per current guidelines. For painful or procedural contexts, is favored at 4-5 mg/kg intramuscularly, as it induces sedation while preserving respiratory drive and protective airway reflexes, reducing the likelihood of apnea. Moderate sedation is generally preferred over deep sedation in children under 6 years to maintain spontaneous ventilation and responsiveness, minimizing the need for advanced airway interventions. The (AAP) guidelines, from 2019 and current as of 2025, emphasize pre-procedure fasting (NPO) protocols tailored to age—such as clear liquids up to 2 hours before for children over 6 months—to balance aspiration risk with prevention, alongside mandatory use of for continuous respiratory monitoring during moderate to deep sedation. These measures contribute to high success rates, with sedation achieving procedural completion in approximately 85-95% of cases for non-painful interventions like or . Post-COVID-19 adaptations have incorporated for remote pre-sedation assessments and parental education in 2023 protocols, enhancing access while mitigating infection risks in outpatient settings. Pharmacogenomic considerations, such as variants affecting (present in about 10% of children), inform personalized dosing for adjunct analgesics to avoid under- or over-sedation. Paradoxical reactions to benzodiazepines, manifesting as agitation or hyperactivity, occur in 1-2% of preschool-aged children, often linked to higher doses or younger age, underscoring the need for alternative agents like in susceptible patients.

Sedation in Elderly and Comorbid Patients

Elderly patients exhibit age-related physiological changes that significantly impact sedation pharmacokinetics and pharmacodynamics, necessitating tailored approaches to minimize risks. Glomerular filtration rate typically declines by approximately 50% from young adulthood to old age, contributing to reduced drug clearance and prolonged effects of sedatives. For benzodiazepines, this results in extended half-lives, often exceeding 20 hours for long-acting agents like diazepam due to diminished hepatic and renal metabolism. Frailty assessments, such as the modified Frailty Index or Groningen Frailty Indicator, guide dose reductions; for instance, propofol induction doses are commonly adjusted to 0.5-1 mg/kg in frail elderly patients to account for heightened sensitivity and avoid hemodynamic instability. Comorbid conditions further complicate sedation in this population, requiring agent-specific adjustments. In renal impairment, such as , lipophilic opioids like are preferred over due to the absence of active metabolites and lower accumulation risk, though careful titration remains essential. Hepatic dysfunction similarly prolongs sedative effects, prompting avoidance of high-clearance drugs and preference for those with hepatic-independent elimination. In obese elderly patients, increased leads to a higher for lipophilic sedatives like , potentially delaying recovery; (BIS) monitoring is crucial to maintain target sedation depths and prevent overdose. Clinical strategies emphasize minimal effective sedation to preserve and , particularly in comorbid elderly. is favored for cardiac patients owing to its α2-adrenergic agonism, which provides sedation and analgesia with minimal respiratory depression compared to benzodiazepines or . Slower of agents is recommended to accommodate reduced clearance. Outcomes highlight elevated risks, with postoperative incidence in sedated elderly ranging from 15% to 50%, influenced by sedative choice and depth. The 2023 American Geriatrics Society (AGS) , with 2025 updates to the companion Alternatives , explicitly flag high-risk sedatives, including benzodiazepines and first-generation antihistamines, as potentially inappropriate in older adults due to associations with falls, fractures, and . Comorbidity-specific protocols, such as those for (COPD), advocate cautious use of sedatives to avoid exacerbating respiratory compromise, with algorithms prioritizing non-benzodiazepine alternatives and close monitoring of oxygenation. Polypharmacy exacerbates sedation risks in elderly patients with comorbidities, particularly when sedatives interact with anticholinergics, increasing fall incidence by up to 20% through enhanced drowsiness and impaired balance. Comprehensive medication reviews are essential to deprescribe such combinations and mitigate adverse events.

Safety, Risks, and Management

Adverse Effects and Complications

Sedation, while essential for patient comfort and procedural success, carries risks of adverse effects and complications that vary by agent, dose, patient factors, and depth of sedation. These can range from mild and transient to severe and life-threatening, with respiratory depression being the most frequent immediate concern across sedation levels. Cardiovascular instability and neurological effects also occur, particularly with certain agents like and benzodiazepines. Long-term consequences, such as and psychological sequelae, may emerge in prolonged use, especially in intensive care settings. Serious adverse events are rare across levels, with rates <1 per 10,000 for events like ; minor respiratory events occur in ~0.1-1% of moderate/deep sedation cases, per large registries. Respiratory complications are among the most common adverse effects of sedation, primarily due to central depression of ventilatory drive and upper airway obstruction. occurs in ~1-5% of moderate sedation cases, often detected early by . In procedural sedation contexts, such as GI endoscopy under conscious sedation, respiratory events including affect ~10-20% of patients, with obstructive events predominating. Apnea, a complete cessation of , is rarer but more critical, occurring in <1% of deep sedation episodes requiring intervention. These events can lead to hypoxia and if unaddressed. Cardiovascular adverse effects stem from the vasodilatory and properties of common sedatives. , often resulting from peripheral , occurs in ~25% of cases involving infusion in ICU settings. In contrast, , an used for ICU sedation, is associated with in up to 42% of patients due to reduced sympathetic outflow, though rates may be comparable to in some cohorts. These hemodynamic changes are more pronounced in deep sedation and can exacerbate underlying comorbidities. Other immediate complications include paradoxical excitation and rare allergic responses. Paradoxical reactions to benzodiazepines, manifesting as agitation, restlessness, or , affect <1% of patients, particularly those with predisposing factors like advanced age or , and are thought to arise from disinhibitory effects on limbic structures. Post-sedation cognitive dysfunction, including and memory impairment, occurs in ~5-15% of elderly patients as and typically resolves within 24-48 hours, attributed to residual GABAergic effects disrupting . Anaphylaxis, though uncommon at ~1 in 60,000 administrations, can occur with agents like due to IgE-mediated responses to its emulsion components. Long-term effects are particularly relevant in chronic or ICU sedation scenarios exceeding 7 days. Prolonged exposure increases dependency risk through tolerance to GABA agonists, with deeper sedation associated with higher /PTSD risk in ICU (~10-30% overall PTSD in survivors). , resulting from impaired airway protection, complicates 0.03-0.05% (1 in 2,000-3,000) of sedated cases, with higher rates in deep sedation due to reduced gag reflex. Recent studies (2023-2025) highlight from extended GABA agonist use, including neuronal in animal models extrapolated to humans, suggesting potential for lasting synaptic alterations. Additionally, sedation may disrupt gut composition, delaying recovery via altered microbiota-brain axis signaling and increased inflammation, as observed in emerging on anesthesia's gut health impacts.

Monitoring and Guidelines

Monitoring during sedation involves continuous assessment of physiological parameters to ensure patient safety and detect early signs of complications. Key monitoring includes to measure (SpO2), which should be maintained above 92-95% in most cases, and measurements every 5 minutes to track hemodynamic stability. , which assesses end-tidal CO2 (ETCO2) via waveform analysis, has been a standard for evaluating ventilation adequacy during moderate and deep sedation since the (ASA) updated its guidelines in 2011, allowing for early detection of or apnea. Additionally, depth-of-sedation indices like the (BIS), derived from processed EEG signals, provide an objective measure with moderate-to-strong correlation (r ≈ 0.6-0.8) to clinical sedation scales such as the (RASS), typically targeting BIS values of 70-90 for adequate procedural sedation. Emerging AI-enhanced monitoring tools, such as closed-loop systems automating sedative dosing based on real-time , have FDA authorization as of 2024 for depth prediction, providing alerts for deviations. Guidelines for sedation emphasize standardized protocols to minimize risks. The ASA Continuum of Depth of Sedation, which delineates levels from minimal to deep sedation and general , was referenced in the 2023 ASA statement distinguishing Monitored Anesthesia Care (MAC) from moderate sedation, particularly for outpatient settings, stressing the need for provider qualifications and rescue capabilities (updated 2024 to include AI integration). The requires credentialing for providers administering moderate or deep sedation, ensuring they are competent in patient assessment, monitoring, and , with privileges aligned to . Recovery from sedation follows criteria like the modified Aldrete score, where a total of ≥9 (out of 10) across activity, respiration, circulation, consciousness, and indicates readiness for discharge from the post-anesthesia care unit. Provider roles are delineated by sedation depth to match expertise with risk. Registered nurses (RNs) may administer minimal sedation (anxiolysis) under physician orders, while moderate sedation typically requires supervision by a qualified physician or advanced practice provider; deep sedation is reserved for physicians, such as anesthesiologists or those with specific privileges, due to the potential for loss of protective reflexes. Emergency preparedness includes availability of reversal agents, such as at an initial dose of 0.2 mg IV over 15 seconds for reversal, repeated as needed up to 1 mg total, to promptly restore if oversedation occurs (2025 updates include expanded use of for residual neuromuscular blockade in transitions to deeper levels). In resource-limited settings, the (WHO) endorses mandatory during and sedation as part of its Safe Surgery Saves Lives initiative, updated through global quality improvement projects to address gaps in low- and middle-income countries (2024 revision incorporates telemedicine for remote monitoring). Quality metrics demonstrate the impact of these practices; for instance, a 2022 service evaluation found that implementation reduced adverse events during moderate sedation by 50% ( 0.50, 95% CI 0.29-0.86), primarily by mitigating hypoxia incidents.

References

  1. https://www.cancer.gov/publications/dictionaries/cancer-terms/def/sedation
  2. https://emedicine.medscape.com/article/809993-overview
  3. https://www.asahq.org/standards-and-practice-parameters/statement-on-continuum-of-depth-of-sedation-definition-of-general-anesthesia-and-levels-of-sedation-analgesia
  4. https://www.ncbi.nlm.nih.gov/books/NBK551685/
  5. https://www.hopkinsmedicine.org/health/treatment-tests-and-therapies/procedural-sedation
  6. https://medlineplus.gov/ency/article/007409.htm
  7. https://www.chp.edu/our-services/sedation-services/medications
  8. https://my.clevelandclinic.org/health/treatments/24880-sedative
  9. https://pmc.ncbi.nlm.nih.gov/articles/PMC4272880/
  10. https://pmc.ncbi.nlm.nih.gov/articles/PMC2424120/
  11. https://www.asahq.org/~/media/sites/asahq/files/public/resources/standards-guidelines/practice-guidelines-for-sedation-and-analgesia-by-non-anesthesiologist.pdf
  12. https://www.unodc.org/unodc/en/data-and-analysis/bulletin/bulletin_1967-01-01_3_page004.html
  13. https://pmc.ncbi.nlm.nih.gov/articles/PMC5478244/
  14. https://obgynkey.com/the-history-of-sedation/
  15. https://inhn.org/about/central-office-cordoba-unit/education/thomas-a-ban-neuropsychopharmacology-in-historical-perspective-education-in-the-field-in-the-post-neuropsychopharmacology-era/educational-series-2-bulletin-5-vignette-2-sedatives-in-the-second-part-of-the-19th-century
  16. https://pmc.ncbi.nlm.nih.gov/articles/PMC1079678/
  17. https://pubmed.ncbi.nlm.nih.gov/24007886/
  18. https://www.sciencemuseum.org.uk/objects-and-stories/medicine/thalidomide
  19. https://academic.oup.com/book/25076/chapter/189244130
  20. https://laskerfoundation.org/winners/discovery-and-development-of-propofol-a-widely-used-anesthetic/
  21. https://www.accessdata.fda.gov/drugsatfda_docs/nda/99/21-038_Precedex.cfm
  22. https://asa.org.au/wp-content/uploads/2024/09/Copy-of-Anaesthesia-History-Timeline-2024-Feb-29.pdf
  23. https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-fda-review-results-new-warnings-about-using-general-anesthetics-and
  24. https://pmc.ncbi.nlm.nih.gov/articles/PMC7398847/
  25. https://www.researchgate.net/publication/283448642_Target-Controlled_Infusion_A_Mature_Technology
  26. https://pmc.ncbi.nlm.nih.gov/articles/PMC12188803/
  27. https://pmc.ncbi.nlm.nih.gov/articles/PMC3227310/
  28. https://www.ncbi.nlm.nih.gov/books/NBK537321/
  29. https://pmc.ncbi.nlm.nih.gov/articles/PMC12160028/
  30. https://pmc.ncbi.nlm.nih.gov/articles/PMC8122992/
  31. https://pmc.ncbi.nlm.nih.gov/articles/PMC11529737/
  32. https://pmc.ncbi.nlm.nih.gov/articles/PMC4554966/
  33. https://www.ncbi.nlm.nih.gov/books/NBK554540/
  34. https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212295Orig1s000SumR.pdf
  35. https://pmc.ncbi.nlm.nih.gov/articles/PMC9879693/
  36. https://www.droracle.ai/articles/157184/procedural-sedation
  37. https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/211844s005lbl.pdf
  38. https://www.ncbi.nlm.nih.gov/books/NBK470159/
  39. https://onlinelibrary.wiley.com/doi/full/10.1046/j.1365-2710.1999.00247.x
  40. https://www.clinpgx.org/pathway/PA165111375
  41. https://pubmed.ncbi.nlm.nih.gov/10667451/
  42. https://pubmed.ncbi.nlm.nih.gov/22145708/
  43. https://pubmed.ncbi.nlm.nih.gov/16854557/
  44. https://pubmed.ncbi.nlm.nih.gov/28626012/
  45. https://pubmed.ncbi.nlm.nih.gov/22747535/
  46. https://pubmed.ncbi.nlm.nih.gov/33329/
  47. https://www.sciencedirect.com/science/article/pii/S2589537023005941
  48. https://pubmed.ncbi.nlm.nih.gov/38907529/
  49. https://www.sciencedirect.com/science/article/pii/S0021925820751070
  50. https://pmc.ncbi.nlm.nih.gov/articles/PMC9650205/
  51. https://www.sciencedirect.com/topics/nursing-and-health-professions/ramsay-sedation-scale
  52. https://www.atsjournals.org/doi/10.1164/rccm.2107138
  53. https://www.sciencedirect.com/topics/medicine-and-dentistry/bispectral-index-monitoring
  54. https://pubmed.ncbi.nlm.nih.gov/16393221/
  55. https://www.asahq.org/standards-and-practice-parameters/standards-for-basic-anesthetic-monitoring
  56. https://publications.aap.org/pediatrics/article/143/6/e20191000/37173/Guidelines-for-Monitoring-and-Management-of
  57. https://pmc.ncbi.nlm.nih.gov/articles/PMC2778460/
  58. https://www.pemj.org/journal/view.php?number=189
  59. https://www.drugs.com/dosage/propofol.html
  60. https://www.rch.org.au/clinicalguide/guideline_index/Nitrous_Oxide_Oxygen_Mix/
  61. https://pmc.ncbi.nlm.nih.gov/articles/PMC12034585/
  62. https://www.ncbi.nlm.nih.gov/books/NBK470551/
  63. https://patents.google.com/patent/US11497711B2/en
  64. https://pubmed.ncbi.nlm.nih.gov/24766744/
  65. https://www.nature.com/articles/s41598-024-56863-z
  66. https://www.drjackbodie.com/oral-sedation-vs-iv-sedation/
  67. https://www.dentsed.com/oral-sedation-vs-iv-sedation-which-option-is-right-for-you/
  68. https://pmc.ncbi.nlm.nih.gov/articles/PMC3558570/
  69. https://www.e-ce.org/journal/view.php?number=6599
  70. https://www.sciencedirect.com/science/article/abs/pii/S0016510704003499
  71. https://pmc.ncbi.nlm.nih.gov/articles/PMC3045881/
  72. https://publications.aap.org/hospitalpediatrics/article/13/10/e301/193965/Nonpharmacological-Interventions-to-Reduce
  73. https://www.jmirs.org/article/S1939-8654%2822%2900208-9/fulltext
  74. https://pmc.ncbi.nlm.nih.gov/articles/PMC4690614/
  75. https://www.merckmanuals.com/professional/injuries-poisoning/how-to-do-skin-soft-tissue-and-minor-surgical-procedures/how-to-incise-and-drain-an-abscess
  76. https://www.sciencedirect.com/science/article/am/pii/S221253452200123X
  77. https://scai.org/quality-improvement-tools/qi-tips/moderate-sedation-practices-adult-patients-cardiac
  78. https://pmc.ncbi.nlm.nih.gov/articles/PMC6923237/
  79. https://www.giejournal.org/article/S0016-5107%2810%2902108-5/fulltext
  80. https://publishing.emanresearch.org/CurrentIssuePDF/EmanPublisher_1_6062angiotherapy-7110317.pdf
  81. https://www.sciencedirect.com/science/article/pii/S2352556825000153
  82. https://pmc.ncbi.nlm.nih.gov/articles/PMC9917582/
  83. https://www.sccm.org/clinical-resources/guidelines/guidelines/guidelines-for-the-prevention-and-management-of-pa
  84. https://www.uptodate.com/contents/sedative-analgesia-in-ventilated-adults-management-strategies-agent-selection-monitoring-and-withdrawal/print
  85. https://www.sccm.org/clinical-resources/guidelines/guidelines/focused-update-padis-guideline
  86. https://pubmed.ncbi.nlm.nih.gov/10816184/
  87. https://emcrit.org/ibcc/pain/
  88. https://ccforum.biomedcentral.com/articles/10.1186/s13054-019-2394-9
  89. https://pmc.ncbi.nlm.nih.gov/articles/PMC7065504/
  90. https://www.aafp.org/pubs/afp/issues/2004/0315/p1443.html
  91. https://sccm.org/clinical-resources/iculiberation-home/abcdef-bundles
  92. https://med.virginia.edu/pediatrics/wp-content/uploads/sites/237/2015/12/200001.pdf
  93. https://www.ncbi.nlm.nih.gov/books/NBK572100/
  94. https://pmc.ncbi.nlm.nih.gov/articles/PMC11529734/
  95. https://link.springer.com/article/10.1007/s40268-025-00522-9
  96. https://www.annemergmed.com/article/S0196-0644(10)01827-5/fulltext
  97. https://pmc.ncbi.nlm.nih.gov/articles/PMC11310124/
  98. https://pmc.ncbi.nlm.nih.gov/articles/PMC11562862/
  99. https://www.sciencedirect.com/science/article/pii/S075333222100843X
  100. https://ekja.org/journal/view.php?doi=10.4097/kjae.2013.65.1.9
  101. https://link.springer.com/article/10.1007/s40495-025-00425-y
  102. https://pmc.ncbi.nlm.nih.gov/articles/PMC11954733/
  103. https://www.mdpi.com/2076-3417/15/11/6052
  104. https://pmc.ncbi.nlm.nih.gov/articles/PMC7753951/
  105. https://www.nature.com/articles/s41598-025-10172-1
  106. https://pmc.ncbi.nlm.nih.gov/articles/PMC12086269/
  107. https://www.cureus.com/articles/405821-comparing-the-efficacy-and-safety-of-dexmedetomidine-versus-propofol-for-sedation-in-adult-patients-undergoing-cardiac-procedures-a-systematic-review
  108. https://journals.lww.com/md-journal/fulltext/2021/06040/postoperative_delirium_after_long_term_general.14.aspx
  109. https://www.americangeriatrics.org/media-center/news/ags-releases-new-beers-criteriar-alternatives-list-support-safer-prescribing
  110. https://agsjournals.onlinelibrary.wiley.com/doi/10.1111/jgs.18372
  111. https://pmc.ncbi.nlm.nih.gov/articles/PMC7173985/
  112. https://pmc.ncbi.nlm.nih.gov/articles/PMC4228551/
  113. https://pmc.ncbi.nlm.nih.gov/articles/PMC4755157/
  114. https://pmc.ncbi.nlm.nih.gov/articles/PMC6947169/
  115. https://publications.aap.org/pediatrics/article/118/3/1087/69396/Incidence-and-Nature-of-Adverse-Events-During
  116. https://www.liebertpub.com/doi/10.4187/respcare.05723
  117. https://pmc.ncbi.nlm.nih.gov/articles/PMC9470789/
  118. https://www.nejm.org/doi/full/10.1056/NEJMoa2024922
  119. https://www.sciencedirect.com/science/article/pii/S1875459711000981
  120. https://jamanetwork.com/journals/jama/fullarticle/1105080
  121. https://pubmed.ncbi.nlm.nih.gov/15460178/
  122. https://pubmed.ncbi.nlm.nih.gov/15762814/
  123. https://ccforum.biomedcentral.com/articles/10.1186/cc8907
  124. https://pmc.ncbi.nlm.nih.gov/articles/PMC12191853/
  125. https://pmc.ncbi.nlm.nih.gov/articles/PMC12167312/
  126. https://anest.ufl.edu/2025/07/21/research-on-anesthesias-impact-on-brain-and-gut-health-featured-at-2025-world-congress-of-neuropsychopharmacology/
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.